PREPINTEST: Efficacy of Small Bowel Preparation in Capsule Endoscopy

Sponsor
University Hospital, Brest (Other)
Overall Status
Completed
CT.gov ID
NCT01267981
Collaborator
Ministry of Health, France (Other)
858
17
3
64
50.5
0.8

Study Details

Study Description

Brief Summary

The best preparation of small bowel is still unknown. The primary aim of this study is to evaluate the polyethylene glycol (PEG) impact of small bowel preparation for unexplained gastrointestinal bleeding exploration. Three different preparations are evaluated in this study.

Condition or Disease Intervention/Treatment Phase
  • Drug: Standard diet
  • Drug: Standard Diet + 500 ml of polyethyleneglycol
  • Drug: Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol
Phase 3

Detailed Description

Now days, the endoscopic video-capsule is the more appropriate exam for unexplained gastrointestinal bleeding exploration. The responsible damage of this unexplained bleeding are frequently small vascular damages, hard to be detected in the bowel or ulcerations or tumors. The exam quality can be limited by food residues, bubbles or bile.

30% of damage are probably undetectable because of a lack of visibility. An efficient preparation will probably increased the quality of the video-capsule exploration.

The bowel exploration by endoscopy video-capsule will be realized in the usual condition. The study included 4 steps:

  1. Inclusion

  2. Randomization

  3. Video-capsule exploration

  4. Reading of the video-capsule exam by endoscopist doctors who are in blind.

Study Design

Study Type:
Interventional
Actual Enrollment :
858 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Impact of Small Bowel Preparation Using Polyethylene Glycol for Endoscopic Video-capsule (EVC)Exploration in Unexplained Gastrointestinal Bleedings
Study Start Date :
Sep 1, 2010
Actual Primary Completion Date :
Jan 1, 2016
Actual Study Completion Date :
Jan 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Preparation 1

Standard diet: the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water.

Drug: Standard diet
After the lunch the day before the exploration, drink only clear liquids and stop solid food. From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.

Active Comparator: Preparation 2

Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water. 500 ml of polyethylene glycol 30 minutes after the ingestion of video-capsule endoscopy.

Drug: Standard Diet + 500 ml of polyethyleneglycol
Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.

Active Comparator: Preparation 3

Standard diet : the day before video-capsule exploration : Drink only clears liquids after the lunch, fasting from 22 hours except usual drugs with a mouthful water. 2 liters of polyethylene glycol between 7 pm and 9 pm. 500 ml of polyethylene glycol, 30 minutes after the ingestion of video-capsule endoscopy.

Drug: Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol
apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.

Outcome Measures

Primary Outcome Measures

  1. Compare the frequencies of the diagnoses of clinically significant lesions [at the end of video-capsule exploration]

    Compare the frequencies of the diagnoses of clinically significant lesions (P1 or P2)obtained with and without polyethylene glycol preparation for patients investigated by video-capsule endoscopy who have an unexplained digestive bleeding.

Secondary Outcome Measures

  1. The quality of the preparation and visibility of the bowel [at the end of video-capsule exploration]

    Demonstrate an improvement in preparation quality and bowel visibility in the various segments of small bowel examined by video-capsule endoscopy

  2. The clinical tolerance [8 days after video-capsule exploration]

    Evaluate the clinical tolerance and the acceptability of the bowel preparation with oral polyethylene glycol solution

  3. The number of all the observed lesions [at the end of video-capsule exploration]

    Estimate the number of all the observed lesions on the recording according to their hemorrhagic potential.

  4. Compare different times [at the end of video-capsule exploration]

    Compare gastric emptying time, the bowel transit time and the percentage complete medical exploration of small bowel for every group of patients (ileo- cecal valve exceeded).

  5. Crossing (yes or no) of ileo-cecal valve by the EVC [At the end of video-capsule exploration]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age >= 18 years old.

  • Patients who have an indication for video-capsule endoscopy exploration for unexplained gastrointestinal bleeding associated with anaemia (man : haemoglobin <13 g/dl and woman haemoglobin <12g/dl)

  • Less than one year Endoscopic assessment by colonoscopy and gastroscopy

  • Not participated to an another clinic study.

  • Written consent.

Exclusion Criteria:
  • Age<18 years old.

  • General physical health deterioration such as dehydration or cardiac insufficiency.

  • Clinical or radiological suspicion of digestive stenosis.

  • Oral iron taking in the 4 days before video-capsule exploration.

  • Functional or organic disorders of the gulp

  • Pregnant women.

  • Sensibility known about the polyethylene glycol.

  • No signed consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier d'Avignon Avignon France 84000
2 Cabinet privé Beziers France
3 Centre Hospitalier d'Avicenne Bobigny France 93000
4 CHOLET Brest France 29200
5 CHRU de Lille Lille France 59037
6 Saint Philibert Hospital Lomme France 59160
7 CH Bretagne Sud Lorient France 56100
8 Edouard Herriot Hospital Lyon France 69437
9 Hôpital de La Conception Marseille France 13274
10 Hôpital de la Timone Marseille France 13385
11 Centre Hospitalier Universitaire de Nice Nice France 06202
12 Hôpital Cochin Paris France 75014
13 Höpital Européen Geores Pompidou Paris France 75015
14 CH de Cornouaille Quimper Quimper France 29000
15 Centre Hospitalier de Saint Brieuc Saint Brieuc France 22000
16 Hôpital Privé de L'Est Lyonnais Saint Priest France 69800
17 CH Bretagne Atlantique Vannes France 56017

Sponsors and Collaborators

  • University Hospital, Brest
  • Ministry of Health, France

Investigators

  • Principal Investigator: Franck CHOLET, MD, CHRU Brest

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT01267981
Other Study ID Numbers:
  • RB 09.091
First Posted:
Dec 29, 2010
Last Update Posted:
Jun 7, 2016
Last Verified:
Jun 1, 2016
Keywords provided by University Hospital, Brest
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2016